AML treatment is moving from being a standard treatment to a personalised treatment. Dr Manos Nikolousis, Clinical Director at Haematology / Stem cell transplantation Heart of England NHS Trust talks about these advancements.
Dr Manos Nikolousis discusses new drugs... - Leukaemia Support
Dr Manos Nikolousis discusses new drugs now available to treat Acute Myeloid Leukaemia (AML)
![HAIRBEAR_UK profile image](https://images.hu-production.be/avatars/6e6fc509981a0df392fc4c6d44143a79_small@2x_100x100.jpg)
![](https://images.hu-production.be/post/post_de3b43b8cf6f45038a671321331412f9_636806484063262000.jpg)
Written by
![HAIRBEAR_UK profile image](https://images.hu-production.be/avatars/6e6fc509981a0df392fc4c6d44143a79_small@2x_100x100.jpg)
HAIRBEAR_UK
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
I think the move from standard treatment to personalised treatment is brilliant and definitely the way forward. Thanks for this and take care.